Tech Company Financing Transactions
Toragen Funding Round
On 10/1/2022, Toragen raised $5.4 million in Seed investment from private investors.
Transaction Overview
Company Name
Announced On
10/1/2022
Transaction Type
Venture Equity
Amount
$5,400,000
Round
Seed
Investors
private investors (Lead Investor) (Paul Engler)
Proceeds Purpose
The company intends to use the funds to conduct its Phase I clinical trial with the lead drug candidate, to advance pre-clinical work on its compounds, for payroll for the research, development and management teams as well as general corporate overhead.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10210 Campus Point Dr. 150
San Diego, CA 92122
USA
San Diego, CA 92122
USA
Phone
Undisclosed
Website
Email Address
Overview
Toragen, a San Diego, CA-based biotechnology company targeting the root cause of virally induced cancers. Our team is comprised of industry leaders with decades of experience in early stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sandra Coufal
Chief Financial Officer
Cheryl Collett
Founder
Andrew Sharabi
VP - R & D
Richard Lumpkin
Browse more venture capital transactions:
Prev: 10/1/2022: CXL Ophthalmics venture capital transaction
Next: 10/1/2022: PetPair venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs